Red Wine Consumption Linked to Lower Risk of Inflammatory Bowel Disease: Study
A study published in Gut found that red wine consumption may be associated with a reduced risk of developing inflammatory bowel disease (IBD). Researchers observed that individuals who consumed red wine had a lower likelihood of developing IBD compared with non-consumers. The potential protective effect is thought to be related to red wine’s polyphenols and antioxidant compounds, which may help modulate gut inflammation and support a healthier intestinal microbiome. However, the findings show an association rather than a cause-and-effect relationship, and further research is needed to confirm whether red wine directly contributes to lowering IBD risk. The study was conducted by Jie Chen and colleagues.
An intensive, multi-center, prospective cohort study was conducted with a large number of 455,417 individuals that were closely observed over time in terms of their risk of developing IBD using Cox proportional hazards regression model. In order to determine the specific impact of alcohol metabolism on the biological system, researchers developed an innovative "acetaldehyde burden score" by assessing the functional variants of alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH) enzymes in terms of their accuracy by means of expression quantitative trait loci (eQTL) and proteomics data.
The study subjects were divided into several subgroups according to the level of their metabolic acetaldehyde burden. In order to corroborate the results of such an extensive epidemiological study and to prove the existence of true causal biological mechanisms, the research team conducted genetic and metabolomic studies and carried out experiments both in vivo on mice and in vitro by means of human colonic organoids.
Key findings:
- Risk measures were estimated based on standard deviation increases in red wine intake, and one such increment translates into exactly 59.4 grams per week of pure alcohol intake.
- In people having a low metabolic burden score and thus low production and rapid metabolism of acetaldehyde, each SD increment in red wine intake was found to lower the risk of developing Crohn's disease by 20% (95% CI, 7% to 31%).
- In those possessing a high metabolic burden score, the same amount of red wine intake led to an alarming 38% increase in the risk of Crohn’s disease (95% CI, 13% to 70%).
- These opposing risk ratios were supported by in vivo and in vitro studies that found that manual stimulation and inhibition of aldehyde dehydrogenase enzyme activity affected the severity of colitis.
Thus, the burden of acetaldehyde metabolism alters vulnerability to alcohol-induced IBD and stresses the need to take into account individual differences in alcohol metabolism in designing precision prevention strategies for IBD. The above-described multi-platform study is an absolutely necessary empirical basis for contemporary clinical gastroenterology, demonstrating that the role of lifestyle risk factors cannot be assessed without studying their metabolizing enzymes.
Reference:
Chen, J., Guo, Y., Hu, J., Ye, S., Yao, J., Yanai, H., Jairath, V., Peyrin-Biroulet, L., Dan, L., Li, X., Wang, X., & Magro, F. (2026). Combined acetaldehyde metabolism burden modifies IBD susceptibility to alcohol consumption. Gut, gutjnl-2026-338262. https://doi.org/10.1136/gutjnl-2026-338262
